---
title: Preclinical efficacy of carfilzomib in BRAF-mutant colorectal cancer models
date: '2024-02-13'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38348572/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20240213170620&v=2.18.0
source: heidelberg[Affiliation]
description: Serine/threonine-protein kinase B-raf (BRAF) mutations are found in 8-15%
  of colorectal cancer patients and identify a subset of tumors with poor outcome
  in the metastatic setting. We have previously reported that BRAF-mutant human cells
  display a high rate of protein production, causing proteotoxic stress, and are selectively
  sensitive to the proteasome inhibitors bortezomib and carfilzomib. In this work,
  we tested whether carfilzomib could restrain the growth of BRAF-mutant colorectal
  ...
disable_comments: true
---
Serine/threonine-protein kinase B-raf (BRAF) mutations are found in 8-15% of colorectal cancer patients and identify a subset of tumors with poor outcome in the metastatic setting. We have previously reported that BRAF-mutant human cells display a high rate of protein production, causing proteotoxic stress, and are selectively sensitive to the proteasome inhibitors bortezomib and carfilzomib. In this work, we tested whether carfilzomib could restrain the growth of BRAF-mutant colorectal ...